Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants

NCT04030533 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Guselkumab (SC): Dose 1
DRUG: Guselkumab (SC): Dose 2
DRUG: Guselkumab (IV): Dose 1
DRUG: Guselkumab (IV): Dose 2
DRUG: Ustekinumab 6 mg/mL

Sponsor

Janssen Research & Development, LLC